Amy Clifton, APRN
Acute Care · Hot Springs, ARNPI 1932351582
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations.
Across 185 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$335
- Pfizer$328
- Novo Nordisk$324
- Novartis$249
- Johnson & Johnson$241
- Merck$215
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,248100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 21 | $335 |
| Pfizer | 22 | $328 |
| Novo Nordisk | 14 | $324 |
| Novartis | 19 | $249 |
| Johnson & Johnson(2 entities) | 15 | $241 |
| Merck | 11 | $215 |
| Amgen | 15 | $214 |
| AstraZeneca | 8 | $200 |
| Philips North America LLC | 9 | $145 |
| Irhythm Technologies, Inc. | 8 | $135 |
| E.r. Squibb & Sons, L.L.C. | 8 | $134 |
| Boston Scientific | 3 | $125 |
| Lexicon Pharmaceuticals, Inc. | 5 | $79 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $76 |
| GSK | 4 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Baxter Healthcare | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Edwards Lifesciences | 2 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $36 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Abiomed | 1 | $26 |
| Biofrontera Inc. | 1 | $19 |
| Medtronic | 1 | $16 |
| Atricure, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Iovance Biotherapeutics, Inc. | 1 | $15 |
| Sanofi | 1 | $13 |
How this compares
$3,248 in reported general payments places this provider in the 85th percentile of 321 acute care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 674 | $538,649 |
| EntrestoSacubitril/Valsartan | 328 | $265,170 |
| Repatha SureclickEvolocumab | 151 | $98,162 |
| JardianceEmpagliflozin | 110 | $83,963 |
| FarxigaDapagliflozin Propanediol | 120 | $82,335 |
| XareltoRivaroxaban | 61 | $54,930 |
| MultaqDronedarone Hcl | 44 | $41,377 |
| BrilintaTicagrelor | 41 | $28,646 |
| Praluent PenAlirocumab | 26 | $13,238 |
| Repatha SyringeEvolocumab | 21 | $11,569 |
| Atorvastatin Calcium | 1,018 | $7,854 |
| Metoprolol Succinate | 623 | $7,373 |
| Bumetanide | 183 | $6,024 |
| Rosuvastatin Calcium | 391 | $5,484 |
| Potassium Chloride | 234 | $4,177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $328 | $538,649674 claims |
| NovartisEntresto | $249 | $265,170328 claims |
| AstraZenecaFarxiga, Brilinta | $200 | $110,980161 claims |
| Boehringer IngelheimJardiance | $335 | $83,963110 claims |
| Johnson & JohnsonXarelto | $241 | $54,93061 claims |
| Sanofi-aventis U.S. LLCMultaq | $62 | $41,37744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 321 acute care providers in Arkansas.
Other acute care in Hot Springs
- Jennifer HocuttHot Springs$15K
- Susan HernandezHot Springs$4K
- Tasha BinnsHot Springs$4K
- Sarah ReynaHot Springs$4K
- Jill AveryLittle Rock$117K
- Lynn FrazierLittle Rock$106K
- Cheryl WalshSpringdale$101K
- Beverly BaxterLittle Rock$95K
- Diane GlendinningLittle Rock$26K
- Beth CrowderLittle Rock$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.